Literature DB >> 20340125

Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists.

Bastian Tewes1, Bastian Frehland, Dirk Schepmann, Kai-Uwe Schmidtke, Thomas Winckler, Bernhard Wünsch.   

Abstract

Cleavage and reconstitution of a bond in the piperidine ring of ifenprodil (1) leads to 7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols, a novel class of NR2B-selective NMDA receptor antagonists. The secondary amine 7-methoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol (12), which was synthesized in six steps starting from 2-phenylethylamine 3, represents the central building block for the introduction of several N-linked residues. A distance of four methylene units between the basic nitrogen atom and the phenyl residue in the side chain results in high NR2B affinity. The 4-phenylbutyl derivative 13 (WMS-1405, K(i)=5.4 nM) and the conformationally restricted 4-phenylcyclohexyl derivative 31 (K(i)=10 nM) represent the most potent NR2B ligands of this series. Whereas 13 shows excellent selectivity, the 4-phenylcyclohexyl derivative 31 also interacts with sigma(1) (K(i)=33 nM) and sigma(2) receptors (K(i)=82 nM). In the excitotoxicity assay the phenylbutyl derivative 13 inhibits the glutamate-induced cytotoxicity with an IC(50) value of 360 nM, indicating that 13 is an NMDA antagonist.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340125     DOI: 10.1002/cmdc.201000005

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  8 in total

1.  Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-meth-oxy-2-methyl-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ols.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

Review 2.  Positron Emission Tomography (PET) Ligand Development for Ionotropic Glutamate Receptors: Challenges and Opportunities for Radiotracer Targeting N-Methyl-d-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA), and Kainate Receptors.

Authors:  Hualong Fu; Zhen Chen; Lee Josephson; Zijing Li; Steven H Liang
Journal:  J Med Chem       Date:  2018-08-27       Impact factor: 7.446

Review 3.  Novel NMDA receptor modulators: an update.

Authors:  Rose M Santangelo; Timothy M Acker; Sommer S Zimmerman; Brooke M Katzman; Katie L Strong; Stephen F Traynelis; Dennis C Liotta
Journal:  Expert Opin Ther Pat       Date:  2012-09-26       Impact factor: 6.674

4.  A ring expansion strategy towards diverse azaheterocycles.

Authors:  Ruirui Li; Bo Li; Hongpeng Zhang; Cheng-Wei Ju; Ying Qin; Xiao-Song Xue; Dongbing Zhao
Journal:  Nat Chem       Date:  2021-07-19       Impact factor: 24.427

5.  Crystal structure of (1S*,2R*)-7-benz-yloxy-2-methyl-3-tosyl-2,3,4,5-tetra-hydro-1H-3-benz-azepin-1-ol: elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists.

Authors:  Bastian Tewes; Bastian Frehland; Roland Fröhlich; Bernhard Wünsch
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2016-04-15

6.  Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor.

Authors:  Ahmed Haider; Irina Iten; Hazem Ahmed; Adrienne Müller Herder; Stefan Gruber; Stefanie D Krämer; Claudia Keller; Roger Schibli; Bernhard Wünsch; Linjing Mu; Simon M Ametamey
Journal:  J Nucl Med       Date:  2018-07-20       Impact factor: 10.057

7.  A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors.

Authors:  Bernhard Wünsch; Guiscard Seebohm; Julian A Schreiber; Dirk Schepmann; Bastian Frehland; Simone Thum; Maia Datunashvili; Thomas Budde; Michael Hollmann; Nathalie Strutz-Seebohm
Journal:  Commun Biol       Date:  2019-11-15

Review 8.  A Review of Molecular Imaging of Glutamate Receptors.

Authors:  Jong-Hoon Kim; János Marton; Simon Mensah Ametamey; Paul Cumming
Journal:  Molecules       Date:  2020-10-16       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.